Mr. Speaker, in the debate on Bill C-2, it is crucial that we focus on the benefits of supervised injection sites like InSite, which has achieved many things.
What would my colleague say are the benefits of having such a site in Canada?
In the House of Commons on November 21st, 2013. See this statement in context.